Yunpeng Liu

A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress

Peter M. Bruno, Yunpeng Liu, Ga Young Park et al. · Nature Medicine · 2017 · 510 citations · Full text

Reductive Stress, Apoptosis, Ribosome Biogenesis Stress +7

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 415 citations · Full text

Surgical Oncology, Hepatology, Medicine +8

Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)

Feng‐Hua Wang, Xiaoli Wei, Jifeng Feng et al. · Journal of Clinical Oncology · 2021 · 336 citations · Full text

Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial

Shun Lü, Jie Wang, Yan Yu et al. · Journal of Thoracic Oncology · 2021 · 264 citations · Full text

Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Shukui Qin, Li Qiu, Shanzhi Gu et al. · ˜The œLancet. Gastroenterology & hepatology · 2021 · 243 citations

Hepatology, Medicine, Pathology +6